Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Sunday 8 November 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

R&D

Digital illustration of the kidneys

Kidney care raises its ambitions at ASN Kidney Week 2026

Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.

Oncology

Digital concept of a lung cancer vaccine

Lung cancer vaccine renews synthetic DNA discussions

pharmaphorum spoke with Dr Amy Walker, CEO of 4basebio, about personalised cancer vaccines and synthetic DNA.

Oncology

Woman with breast cancer and female HCP

How precision medicine treats an overlooked clinical variabl...

In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.

R&D

Challenging the clinical trial plan

Why the best CROs challenge the trial plan and keep challeng...

Too often, oncology trials fail for reasons that could have been anticipated and addressed.

Digital

AI graphic concept

AI is exposing a new digital maturity divide in pharma busin...

As AI adoption increases, it is exposing just how prepared organisations really are to operate in a digitally connected environment.

Articles

Spotlight on... multiple sclerosis (MS)

Spotlight on... multiple sclerosis (MS)

In our central nervous system disorders focus month, Andrea Lisher provides us with an overview of multiple sclerosis (MS), which currently affects around 100,000 people in the UK and 2 million

Articles

The changing environment for pharma and medtech companies in Europe

The changing environment for pharma and medtech companies in...

Rebecca Aris provides an overview of the topics discussed at the recent event held by SFL in London, '

Articles

Personalised medicine

Personalised medicine

Anthony Rowbottom explores 'the new modern era of medicine' – 'individual & personalised medicine'.

Load more results

Sales & Marketing

Sales & Marketing

Solution Spotlight: BrandPRO Biopharma

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Digital

AI graphic concept

AI is exposing a new digital maturity divide in pharma busin...

As AI adoption increases, it is exposing just how prepared organisations really are to operate in a digitally connected environment.

Digital

Radiology scans

Radiology has been optimising the wrong metric

Report turnaround time has become a key metric for diagnostic centres, shaping much of the automation built around their work.

Market Access

Market Access

MDM concept of patient data

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Editor's Picks

UK budget includes £1bn biopharma investment package

HHS doubles down on controversial peptides plan

Lilly's triple G overpowers Ozempic in diabetes trial

UK puts £100m into "world-first" AI biosecurity facility

US gives $99m for Ebola jab project, as cases spread in Africa

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Digital concept of a lung cancer vaccine

Lung cancer vaccine renews synthetic DNA discussions

pharmaphorum spoke with Dr Amy Walker, CEO of 4basebio, about personalised cancer vaccines and synthetic DNA.

Oncology

Woman with breast cancer and female HCP

How precision medicine treats an overlooked clinical variabl...

In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.

Oncology

On the benefits of earlier oncological intervention, with Johnson & Johnson

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Patients

Deep Dive

Why are so few sickle cell disease patients using a widely available treatment?

Why are so few sickle cell disease patients using a widely a...

Patients

TMS being given to female patient by female HCP.

TMS works. Why do fewer than 1% of eligible patients get it?

A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.

Deep Dive

Finding the right patients: The case for stratification in rare disease

Finding the right patients: The case for stratification in r...

R&D

R&D

Digital illustration of the kidneys

Kidney care raises its ambitions at ASN Kidney Week 2026

Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.

R&D

Challenging the clinical trial plan

Why the best CROs challenge the trial plan and keep challeng...

Too often, oncology trials fail for reasons that could have been anticipated and addressed.

R&D

Cargo vessels in Straight of Hormuz

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

Editor's Picks

UK budget includes £1bn biopharma investment package

HHS doubles down on controversial peptides plan

Lilly's triple G overpowers Ozempic in diabetes trial

UK puts £100m into "world-first" AI biosecurity facility

US gives $99m for Ebola jab project, as cases spread in Africa

News

Zepbound and Foundayo

Lilly partners with Hims & Hers on obesity drug sales

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company